Precigen Inc. (PGEN) PT Raised to $9 at Citizens- PAPZIMEOS Can Dominate RRP Market

Citizens analyst Jason N. Butler raised the price target on Precigen Inc. (NASDAQ: PGEN) to $9.00 (from $8.00) while maintaining a Market Outperform rating.

The analyst commented, "PAPZIMEOS already stakes claim as front-line standard-of-care in RRP; we reiterate our Market Outperform rating and increase our risk-adjusted sum-of-the-parts derived price target to $9 from $8. Yesterday afternoon, Precigen reported 4Q25 business updates and financial results. Importantly, management provided guidance for 1Q26 PAPZIMEOS sales of >$18MM and reiterated that the company has sufficient funding through cash flow break-even. All key commercial metrics are impressive, in our view, including patient engagement/enrollment in hubs, reimbursement access, and advocacy support. Furthermore, engaged profiles are broad, including patients who have undergone many surgeries, as well as new/recently diagnosed patients. We continue to believe PAPZIMEOS has potential to dominate the RRP market as the first, and only, approved therapy for recurrent respiratory papillomatosis (RRP)."

You May Also Be Interested In

• Bernstein SocGen Group Starts Terawulf Inc. (WULF) at Outperform
• RBC Capital on Veeva Systems (VEEV) Amid After Hours Selloff on Earnings: 'we are surprised to see shares trade down'
• IDT Corp. (IDT) Tops Q3 EPS by 2c; offer guidance